BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …

Opinion statement The BRAF activating mutation, harbored by approximately 10% of
colorectal cancers (CRC), confers dramatic prognosis to advanced diseases. In early-stage …

BRAF mutations in colorectal cancer have been studied over the past several decades.
BRAF V600E mutation, a class I mutation, is the most common oncogenic BRAF alteration in …

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …

Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world.
It is a heterogeneous disease, which can be classified into different subtypes, characterized …

Background BRAF mutations occur in 5% to 10% of metastatic colorectal cancers and are
biomarkers associated with a poor prognosis. However, the outcomes with standard …

The personalization of cancer care is rooted in the premise that there are subsets of patients
with tumors harboring clinically relevant targets for patient-specific treatments. Colorectal …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …

Simple Summary Colorectal cancer with a mutation in an oncogene BRAF has paid much
attention, as it comprises a population with dismal prognosis since two decades ago. A …

Purpose: BRAF mutations are grouped in activating RAS-independent signaling as
monomers (class 1–V600E) or as dimers (class 2–codons 597/601), and RAS-dependent …